Gene Editing Technology



Steadily, it is very exciting to see that, Gene Editing Technology is leading to new knowledge, new knowhow, new discoveries, good-living conditions, development of new therapies and products to benefit mankind.

On this momentum, I have a pleasure to recall that, the European Patent Office (EPO) intends to grant Dr. Emmanuelle Charpentier, ERS Genomics’ co-founder, together with the University of California and University of Vienna, a patent with very broad claims covering the use of CRISPR-Cas9 technology for gene editing.
I can observe that, the claims intended for grant by the EPO are directed to the widely-used single-guide CRISPR-Cas9 gene editing system and cover uses in both cellular and non-cellular settings, including use in bacteria, plants, animals, and cells from vertebrate animals such as humans.

Popular posts from this blog

Zend Server with developers and DevOps engineers on Google Cloud Platform.

IBM Cloud, Bluemix + Apple Swift for mobile app front-end and back-end development

IBM on Secured Blockchain Services for Financial Services, Government and Healthcare on IBM Cloud